Streetbeat News

Earnings

THTX

Theratechnologies Inc. will announce its Q4 and full year 2024 financial results on February 26, 2025. The company will also provide a business update.

Portfolio Pulse from

February 14, 2025 | 12:45 pm

TFIN

Levi & Korsinsky has initiated an investigation into Triumph Financial, Inc. (NASDAQ:TFIN) for potential federal securities law violations after the company reported earnings that missed estimates.

Portfolio Pulse from

February 14, 2025 | 12:45 pm

MSCI

Levi & Korsinsky has initiated an investigation into MSCI Inc. for potential securities law violations following a significant drop in 4Q profit due to increased operating expenses and employee-related costs.

Portfolio Pulse from

February 14, 2025 | 12:45 pm

GCL

GCL Global Holdings Ltd. (Nasdaq: GCL) released its unaudited financial results for the first half of fiscal year 2025, covering the period ending September 30, 2024.

Portfolio Pulse from

February 14, 2025 | 12:45 pm

ROKU

Roku is expected to experience a significant turnaround, with free cash flow projected to nearly double by 2025. The company is debt-free and its stock is priced at 35x forward free cash flow, making it attractive to institutional investors. Roku's ad business and retail expansion are expected to drive user growth and revenue.

Portfolio Pulse from

February 14, 2025 | 12:30 pm

OPRA

Opera Limited will release its Q4 2024 financial results on February 27, 2025, before the market opens.

Portfolio Pulse from

February 14, 2025 | 12:15 pm

TU

TELUS International's Q4 2024 revenues were flat, but shares rose 10% on February 13, likely due to fears of worse results. Positive cashflows are improving the balance sheet, and investments in generative AI are ongoing.

Portfolio Pulse from

February 14, 2025 | 12:15 pm

TUIFF

TUI has shown a strong recovery post-COVID-19 with a 22% return over the past year and a 13% revenue increase in 1Q25. Despite no current dividend, TUI's fundamentals are improving, with a B+ rating and potential for dividend reinstatement by 2027. The company is undervalued with a P/E of 7x and a price target of €14/share, suggesting a 92% upside in 3 years.

Portfolio Pulse from

February 14, 2025 | 12:15 pm

CLMT

Calumet, Inc. will release its Q4 and FY 2024 earnings on February 28, 2025, with a conference call scheduled for the same day.

Portfolio Pulse from

February 14, 2025 | 12:15 pm

APLS

Apellis Pharmaceuticals will host a conference call on February 28, 2025, to discuss its Q4 and full year 2024 financial results.

Portfolio Pulse from

February 14, 2025 | 12:15 pm